

# Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

## InVivoMab anti-human CD28

RRID:AB\_2687729

Type: Antibody

---

### Proper Citation

(Bio X Cell Cat# BE0248, RRID:AB\_2687729)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2687729](http://antibodyregistry.org/AB_2687729)

**Proper Citation:** (Bio X Cell Cat# BE0248, RRID:AB\_2687729)

**Target Antigen:** CD28

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: in vitro T cell stimulation/activation

**Antibody Name:** InVivoMab anti-human CD28

**Description:** This monoclonal targets CD28

**Target Organism:** human

**Clone ID:** clone 9.3

**Antibody ID:** AB\_2687729

**Vendor:** Bio X Cell

**Catalog Number:** BE0248

**Alternative Catalog Numbers:** BE0248-100MG, BE0248-50MG, BE0248-1MG, BE0248-25MG, BE0248-5MG

**Record Creation Time:** 20260114T192854+0000

**Record Last Update:** 20260706T190410+0000

---

### Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-human CD28.

No alerts have been found for InVivoMab anti-human CD28.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 17 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. *Cancer research*, 85(4), 692.

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. *bioRxiv : the preprint server for biology*.

Scott KA, et al. (2024) Covalent targeting of splicing in T cells. *Cell chemical biology*.

Lim YJ, et al. (2024) MicroRNA-19b exacerbates systemic sclerosis through promoting Th9 cells. *Cell reports*, 43(8), 114565.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. *Immunity*, 56(8), 1955.

Hadley P, et al. (2023) Precise surface functionalization of PLGA particles for human T cell modulation. *Nature protocols*, 18(11), 3289.

Baßler K, et al. (2023) Identification of the novel FOXP3-dependent Treg cell transcription factor MEOX1 by high-dimensional analysis of human CD4+ T cells. *Frontiers in immunology*, 14, 1107397.

Wang Z, et al. (2022) 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells. *Cell stem cell*, 29(4), 515.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.

Guo X, et al. (2021) Effective chimeric antigen receptor T cells against SARS-CoV-2. *iScience*, 24(11), 103295.

Matias MI, et al. (2021) Regulatory T cell differentiation is controlled by ?KG-induced alterations in mitochondrial metabolism and lipid homeostasis. *Cell reports*, 37(5), 109911.

Wang Y, et al. (2021) NAD<sup>+</sup> supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. *Cell reports*, 36(6), 109516.

Vinogradova EV, et al. (2020) An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. *Cell*, 182(4), 1009.

Ahmed R, et al. (2019) A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen. *Cell*, 177(6), 1583.

Li L, et al. (2019) TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy. *Cell metabolism*, 29(1), 103.

Schmidleithner L, et al. (2019) Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction. *Immunity*, 50(5), 1232.

Grandclaudon M, et al. (2019) A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication. *Cell*, 179(2), 432.